Goldman Sachs analyst Davin Thillainathan initiated coverage of CSL (CSLLY) with a Buy rating and A$325.40 price target The firm believes the company’s investments in its immunoglobulin franchise and new product launches in the Behring portfolio are set to increase return on invested capital.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSLLY: